Yelak Biru: Kite and Arcellx have announced plans to commence a Phase III clinical trial for myeloma

Yelak Biru, President and CEO of the International Myeloma Foundation, shared on X: .

“We need more options in the multiple myeloma toolbox: Kite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of anitocabtagene autoleucel (anito-cel), for myeloma.

Anito-cel is a (BCMA CAR) T-cell therapy. Via Clinical Trials Arena.”

Source: Yelak Biru/X